Botulinum Toxin for Palliative Treatment of Epiphora in Patients with Nasolacrimal Duct Obstruction
Journal of the Korean Ophthalmological Society
;
: 1318-1322, 2007.
Article
in Korean
| WPRIM
| ID: wpr-75158
ABSTRACT
PURPOSE:
To describe the use of botulinum toxin injection of the lacrimal gland for palliative treatment of epiphora secondary to nasolacrimal duct obstruction.METHODS:
A prospective non-comparative interventional case series study was designed to include 13 patients with nasolacrimal duct obstruction. Under topical anesthesia botulinum toxin A (1-4unit) was injected into the palpebral lobe of the lacrimal gland via a transconjunctival approach. Patients underwent a Schirmer test and a subjective evaluation of their epiphora symptoms was performed at 0 (baseline), 1, 4 and 12 weeks after injection.RESULTS:
Subjective epiphora scores improved in 10 out of the 13 patients (76.9%). Schirmer test results showed objective reduction in tearing from baseline but did not strongly correlate with the subjective epiphora scores. Transient ptosis were experienced by two patients.CONCLUSIONS:
Botulinum A toxin injection for palliative treatment of epiphora secondary to nasolacrimal duct obstruction is a simple, effective and safe treatment.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Palliative Care
/
Botulinum Toxins
/
Prospective Studies
/
Botulinum Toxins, Type A
/
Anesthesia
/
Lacrimal Apparatus
/
Lacrimal Apparatus Diseases
/
Nasolacrimal Duct
Type of study:
Observational study
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Ophthalmological Society
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS